Australia · Delayed Price · Currency is AUD Nanosonics Earnings Call Transcripts
Fiscal Year 2026
-
Revenue grew 9% year-over-year to AUD 102 million, with strong recurring revenue and operating margin expansion. Guidance for 8%-12% revenue growth is reaffirmed, supported by upgrades, new product launches, and disciplined cost management.
Fiscal Year 2025
-
The meeting highlighted strong financial growth, major product launches (trophon3 and CORIS), and a new share buyback. All board and remuneration resolutions passed with high support. Strategic focus remains on innovation, sustainability, and global expansion, with no dividend declared due to low franking credits.
-
Revenue grew 17% to AUD 198.6 million, with recurring revenue up 20% and profit before tax up 72%. FY 2026 guidance anticipates 8–12% revenue growth, gross margin of 75–77%, and continued investment in innovation, with minimal CORIS revenue expected.
-
Revenue rose 18% year-over-year to AUD 93.6 million, with strong growth in North America and Europe. Full-year revenue guidance was raised to 11%-14%, gross margin improved to 78.5%, and net profit increased 58%. Cash balance stands at AUD 144.5 million, with no debt.
Fiscal Year 2024
-
The meeting reviewed a return to growth in FY 2024, with strong H2 performance, robust margins, and ongoing investment in R&D and sustainability. Strategic focus remains on expanding the trophon base, launching CORIS pending FDA approval, and strengthening governance and diversity. Shareholders discussed regulatory, competitive, and operational risks.
-
Second half FY24 saw a strong revenue rebound, driven by capital unit sales and recurring revenue growth. FY25 guidance targets 8%-12% revenue growth, margin recovery, and continued investment in R&D and M&A, with hospital budget constraints easing but still present.